Previous 10 | Next 10 |
Image source: The Motley Fool. Ziopharm Oncology Inc (NASDAQ: ZIOP) Q1 2021 Earnings Call May 6, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Ziopharm Oncology Inc (ZIOP) Q1 2021 Earnings Call Transcript
ZIOPHARM Oncology, Inc. (ZIOP) Q1 2021 Earnings Conference Call May 6, 2021 04:30 pm ET Company Participants Adam Levy - Executive Vice President, Investor Relations and Corporate Communications Heidi Hagen - Interim Chief Executive Officer Raffaele Baffa - Chief Medical Officer James Huang -...
ZIOPHARM Oncology (ZIOP): Q1 GAAP EPS of -$0.10 beats by $0.01.Cash and cash equivalents, as of March 31, 2021 were $100.1M.Press release. For further details see: ZIOPHARM Oncology EPS beats by $0.01
– Annual shareholder meeting planned for May 19, 2021 – Company to host conference call today at 4:30 pm ET BOSTON, May 06, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), tod...
BOSTON, May 04, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), announced today that Laurence J.N. Cooper, PhD, MD, Scientific Advisor to the Company, will present and participate in an upcoming panel discussion at t...
BOSTON, April 29, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced it will report first quarter 2021 financial results on Thursday, May 6, 2021 after the financial markets close, and host its annual shareholder meeting on May 19, 2021. Details for each is as ...
BOSTON, April 28, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), announced today that Laurence J.N. Cooper, PhD, MD, Scientific Advisor to the Company, was the inaugural presenter at Aldevron’s Virtual Breakt...
Ziopharm Oncology (ZIOP) announces that the first patient was infused in the CD19-Specific Rapid Personalized Manufacturing (“RPM”) CAR-T Phase I Trial, being conducted by Eden BioCell, its joint venture with TriArm Therapeutics.The study is a single center phase I, open-la...
BOSTON and HOUSTON and TAIPEI, Taiwan, April 19, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), announced today that in March, the first patient was infused in the CD19-Specific Rapid Personalized Manufacturing (...
ZIOPHARM Oncology ([[ZIOP]] +0.3%) has entered into a consulting agreement with Laurence Cooper, the former CEO of the company.Previously, Ziopharm announced the departure of Dr. Cooper and implied a potential role for him at the company in a scientific advisory capacity to support ...
News, Short Squeeze, Breakout and More Instantly...
ZIOPHARM Oncology Inc Company Name:
ZIOP Stock Symbol:
NASDAQ Market:
ZIOPHARM Oncology Inc Website:
TCR-T Library Phase 1/2 trial achieved an 87% disease control rate of eight evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all treated patients hunTR® discovered new HLA class I and class II restricted TCRs that recognize d...
TCR-T Library Phase 1/2 trial achieved an 83% disease control rate of six evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all evaluable patients Company to wind down TCR-T Library Phase 1/2 trial and concurrently explore potent...
HOUSTON, June 29, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that the Compan...